Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 343 followers
Latest posts
Last updated about 16 hours ago
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
about 16 hours ago
Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular...
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
1 day ago
After Jenny Pearson’s daughter Elise first had a seizure at 16 months...
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
1 day ago
Italian company the Menarini Group has agreed to pay Chinese insulin maker...
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
1 day ago
Infectious-disease biotech Invivyd has appointed its current chairman, Marc Elia, as CEO.
A year on from Big Pharma’s pull-back from the UK, has anything changed?
1 day ago
September 2025 marked a low point for relations between the U.K. government...
Psilocybin proves promising in neuropathic pain mouse study
2 days ago
Amid the rise of psychedelics in the mental health space, researchers have...
Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
2 days ago
Pfizer has found a new home for an antibody-drug conjugate it acquired...
Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
2 days ago
Roche has decided to pay $190 million upfront for an unusual obesity...
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
2 days ago
AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell...
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
2 days ago
GSK is handing over $110 million upfront to Hutchmed in a deal...
Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’
2 days ago
Ultragenyx had been flying high after its recent FDA approval for Genglycos—but...
Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division
3 days ago
Fortrea has agreed to acquire the early-phase services division of fellow CRO...